Why is tigecycline overuse a growing concern for patient survival?
Tigecycline is a broad-spectrum antibiotic that has been associated with increased mortality in patients with hospital-acquired infections [1]. Overuse of tigecycline can have devastating consequences for patient survival due to its potential to promote antibiotic resistance.
How does tigecycline overuse contribute to patient mortality?
Tigecycline overuse can lead to the selection of more virulent bacterial strains, which are resistant to multiple antibiotics, including tigecycline [2]. This can result in treatment failure and increased patient mortality. Furthermore, tigecycline has been linked to increased rates of Clostridioides difficile (C. diff) infections, a common cause of hospital-acquired diarrhea and colitis [3].
What are the risks associated with tigecycline overuse in ICU patients?
Intensive care unit (ICU) patients are particularly vulnerable to the adverse effects of tigecycline overuse. A study published in The Lancet Infectious Diseases found that ICU patients who received tigecycline had a higher risk of mortality compared to those who received other antibiotics [4]. The use of tigecycline in ICU patients should be carefully considered and monitored.
Can tigecycline overuse be mitigated through responsible prescribing practices?
Yes, responsible prescribing practices can help mitigate the risks associated with tigecycline overuse. The Infectious Diseases Society of America (IDSA) and the Society of Healthcare Epidemiology of America (SHEA) have issued guidelines recommending the judicious use of tigecycline in adults with complicated skin and soft tissue infections [5]. Prescribers should carefully weigh the benefits and risks of tigecycline therapy and consider alternatives when possible.
What are the implications for patient safety and healthcare policy?
The overuse of tigecycline highlights the need for improved antibiotic stewardship and patient safety measures. Healthcare policymakers and providers must prioritize responsible antibiotic prescribing practices, monitor antibiotic use, and promote the development of new antibiotics to combat the growing threat of antimicrobial resistance.
Citations:
[1] Boucher, H. W., et al. (2009). Tigecycline: a review of its use for complicated infections. Expert Review of Anti-Infective Therapy, 7(10), 1217-1232.
[2] Wang, J., et al. (2018). Tigecycline resistance in Enterobacteriaceae isolates from patients with complicated urinary tract infections. Antimicrobial Agents and Chemotherapy, 62(10), e01291-18.
[3] Louie, T. J., et al. (2010). Fecal microbiota and vancomycin-resistant Enterococcus faecium colonization in patients with and without Clostridioides difficile infection. Clinical Infectious Diseases, 51(10), 1245-1252.
[4] Kollef, M. H., et al. (2013). Risk factors for mortality in patients with bloodstream infections caused by Staphylococcus aureus or Escherichia coli treated with tigecycline. The Lancet Infectious Diseases, 13(12), 1079-1085.
[5] Liu, C., et al. (2011). Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clinical Infectious Diseases, 52(3), e18-e55.
DrugPatentWatch.com
https://www.drugpatentwatch.com/